K+S Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
K+S Stock Forecast and Price Target
If the average 2024 price target of 15.90€ recently set by eight prominent experts for K+S is met, there would be a potential upside of approximately 13.65% from the last closing price in April, 2024. The high estimate is 20.00€, and the low is 10.00€. If you're considering investing in SDF stock, it's important to look at its competitors too.
13.65% Upside
K+S Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, K+S's Price has seen an increase, rising from 0.00€ to 0.00€. This represents a growth of 100.00%. Analysts predict that K+S's Fair Value will increase in the upcoming year, reaching 14.75€. This would represent an increase of 100.00%. Over the next seven years, experts predict that K+S's Fair Value will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$147.91 | Buy/Sell | $174.55 | 14.93% |
MRK Stock Forecast | Merck | Outperform |
2
|
$125.78 | Buy/Sell | $130.51 | 10.91% |
AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£109.46 | Buy/Sell | £165.99 | 47.83% |
TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$544.78 | Buy/Sell | $591.94 | 11.33% |
NOVN Stock Forecast | Novartis | Hold |
10
|
CHF85.53 | Buy/Sell | CHF105.00 | 23.11% |
K+S Revenue Forecast for 2023 - 2025 - 2030
In the last two years, K+S's Revenue has seen an increase, rising from 2.43€B to 5.68€B. This represents a growth of 133.40%. In the next year, 16 analysts estimate that K+S's Revenue will decrease by 34.82%, reaching 3.70€B. According to professional forecasts, in 2030, K+S's Revenue will decrease by 27.13%, reaching 4.14€B.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BHP Stock Forecast | BHP Group | Outperform |
1
|
$44.63 | Buy/Sell | $30.06 | -31.75% |
PFE Stock Forecast | Pfizer | Outperform |
2
|
$26.00 | Buy/Sell | $32.87 | 17.31% |
AMGN Stock Forecast | Amgen | Outperform |
4
|
$268.93 | Buy/Sell | $303.65 | 17.97% |
K+S Dividend per Share Forecast for 2023 - 2025 - 2030
K+S's Dividend per Share has seen growth In the last year, going from 0.20€ to 1.00€ – a gain of 400.00% According to 14 analysts, K+S's Dividend per Share will fall by 45.00% in the next year, reaching 0.55€. Professionals believe that By 2030, K+S's Dividend per Share will fall to 0.40€ – a 59.93% decrease from its current value.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.93 | Buy/Sell | $58.15 | 12.41% |
GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$66.76 | Buy/Sell | $87.82 | 22.83% |
GSK Stock Forecast | GSK | Outperform |
12
|
£15.99 | Buy/Sell | £17.30 | 21.95% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
8031 Stock Forecast | Mitsui & | Outperform |
3
|
¥7.13k | Buy/Sell | ¥6.06k | -0.07% |
VALE3 Stock Forecast | Vale | Outperform |
5
|
R$63.36 | Buy/Sell | R$19.16 | -75.05% |
LONN Stock Forecast | Lonza Group | Buy |
16
|
CHF502.80 | Buy/Sell | CHF516.89 | 16.35% |
K+S EBITDA Forecast for 2023 - 2025 - 2030
K+S's EBITDA has grown in the last two years, jumping from -1.62€B to 2.45€B – an increase of 251.76%. 16 analysts predict K+S's EBITDA will decrease by 71.08% in the next year, reaching 709.40€M. By 2030, professionals predict that K+S's EBITDA will decrease by 58.21%, to 1.03€B.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
DD Stock Forecast | DuPont de Nemours | Outperform |
17
|
$73.89 | Buy/Sell | $75.38 | 8.27% |
DSFIR Stock Forecast | DSM-Firmenich | Outperform |
18
|
104.10€ | Buy/Sell | 114.60€ | 15.27% |
NTR Stock Forecast | Nutrien | Outperform |
16
|
C$72.56 | Buy/Sell | C$66.09 | -20.88% |
K+S EBIT Forecast for 2023 - 2025 - 2030
In the last two years, K+S's EBIT has increased by 206.72%, going from -1.92€B to 2.05€B. For the following year, the 11 analysts predict that K+S's EBIT will drop by 86.13%, reaching 284.40€M. In 2030, the professionals' prediction is that SDF's EBIT will decrease by 76.47%, reaching 482.70€M.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
SY1 Stock Forecast | Symrise | Outperform |
18
|
105.40€ | Buy/Sell | 106.97€ | 7.21% |
CF Stock Forecast | CF Industries Holdings | Hold |
3
|
$79.47 | Buy/Sell | $86.20 | 6.96% |
SQM Stock Forecast | Sociedad Química y Minera de ... | Outperform |
17
|
$44.99 | Buy/Sell | $74.26 | 55.59% |
K+S EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, K+S's EPS has seen an increase, rising from -9.42€ to 0.00€. This represents a growth of 100.00%. Analysts predict that K+S's EPS will increase in the upcoming year, reaching 1.01€. This would represent an increase of 100.00%. Over the next seven years, experts predict that K+S's EPS will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
AKZA Stock Forecast | Akzo Nobel N.V. | Outperform |
18
|
66.28€ | Buy/Sell | 79.42€ | 16.93% |
500124 Stock Forecast | Dr. Reddy's Laboratories | Hold |
18
|
Rp5.94k | Buy/Sell | Rp5.67k | 1.81% |
PHOR Stock Forecast | Public Joint-Stock Company Pho... | - |
16
|
руб7.93k | Buy/Sell | руб74.28 | -69.68% |